Edesa Biotech, Inc. (EDSA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Markham, ON, Canada. The current CEO is Pardeep Nijhawan.
EDSA has IPO date of 2010-06-21, 16 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $43.58M.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
